Is Cipla a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Cipla Ltd is a good quality company .

Is Cipla undervalued or overvalued?

The key valuation ratios of Cipla Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Cipla share price return in the past 10 years?

Cipla Ltd share price has appreciated 8.9% annually (CAGR) over the past ten years.

Is Cipla a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Cipla Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Cipla Ltd - Stock Valuation and Financial Performance

Name: Cipla
Brand: Cipla

BSE: 500087 | NSE: CIPLA | Pharmaceuticals & Drugs | Large Cap

Place order

Cipla Share Price

₹1,465.65 -5.70 -0.39%
as on 21-Nov'24 16:59

10 Year X-Ray of Cipla:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	15.3%	13.2%	8.3%	10.2%	11.9%	12.5%	17.9%	17.2%	18.2%	22.8%	-
Value Creation Index ⓘ	0.4	0.2	-0.3	-0.1	0.1	0.1	0.6	0.5	0.6	1.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	11,345	13,595	14,394	15,156	16,362	17,132	19,160	21,763	22,753	25,774	26,174
Sales YoY Gr.	-	19.8%	5.9%	5.3%	8%	4.7%	11.8%	13.6%	4.6%	13.3%	-
Adj EPS ⓘ	13.7	15.4	11.4	16.5	16.4	17.1	29.1	30	32.7	49.3	55.4
YoY Gr.	-	12.3%	-26.4%	45.1%	-0.2%	3.9%	70.4%	3.2%	8.9%	50.8%	-
BVPS (₹) ⓘ	133.4	142.2	155.2	175.9	185.6	194.9	226.7	257.8	289.2	329.7	351.2
Adj Net Profit ⓘ	1,103	1,239	914	1,327	1,325	1,377	2,347	2,422	2,638	3,978	4,475
Cash Flow from Ops. ⓘ	1,173	1,741	2,382	1,463	1,691	3,068	3,755	3,326	3,238	4,134	-
Debt/CF from Ops. ⓘ	1.5	3	1.7	2.8	2.6	0.9	0.5	0.3	0.2	0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	9.6%	9.5%	10.4%	13.3%
Adj EPS ⓘ	15.3%	24.6%	19.2%	50.8%
BVPSⓘ	10.6%	12.2%	13.3%	14%
Share Price	8.9%	24.7%	18%	16.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	10.6	11.1	7.6	9.9	9.1	9	13.8	12.4	11.9	15.9	16.3
Op. Profit Mgn % ⓘ	19.1	18.2	17.6	18.7	18.9	18.7	22.2	20.7	21.9	24.4	25.5
Net Profit Mgn % ⓘ	10.4	9.4	6.6	8.8	8	8	12.2	11.3	11.7	15.6	17.1
Debt to Equity ⓘ	0.2	0.5	0.3	0.3	0.3	0.2	0.1	0	0	0	0
Working Cap Days ⓘ	248	220	200	210	151	140	134	135	146	145	139
Cash Conv. Cycle ⓘ	112	107	106	103	59	53	52	56	52	49	102

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 16.30%

Sales growth is growing at healthy rate in last 3 years 10.39%

Net Profit is growing at healthy rate in last 3 years 19.20%

Sales growth is not so good in last 4 quarters at 8.05%

Latest Financials - Cipla Ltd.

	Standalone	Consolidated
TTM EPS (₹)	52.4	55.4
TTM Sales (₹ Cr.)	14,965	26,174
BVPS (₹.) ⓘ	360.7	351.2
Reserves (₹ Cr.) ⓘ	28,972	28,201
P/BV ⓘ	4.08	4.19
PE ⓘ	28.07	26.55

From the Market
52 Week Low / High (₹)	1165.10 / 1702.00
All Time Low / High (₹)	2.22 / 1702.00
Market Cap (₹ Cr.)	1,18,828
Equity (₹ Cr.)	161.5
Face Value (₹)	2
Industry PE ⓘ	43

Management X-Ray of Cipla:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Cipla

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Cipla

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	11,345	13,595	14,394	15,156	16,362	17,132	19,160	21,763	22,753	25,774
Operating Expenses ⓘ	9,184	11,115	11,919	12,329	13,265	13,951	14,911	17,251	17,763	19,483
Manufacturing Costs	965	1,269	1,445	1,519	1,620	1,699	1,515	1,784	1,944	2,144
Material Costs	4,271	5,090	5,317	5,438	5,784	5,991	7,352	8,496	8,252	8,820
Employee Cost	1,968	2,434	2,634	2,690	2,857	3,027	3,252	3,530	3,830	4,310
Other Costs ⓘ	1,980	2,322	2,523	2,681	3,004	3,233	2,793	3,442	3,737	4,209
Operating Profit ⓘ	2,162	2,480	2,476	2,826	3,097	3,181	4,249	4,512	4,990	6,291
Operating Profit Margin (%)	19.1%	18.2%	17.2%	18.6%	18.9%	18.6%	22.2%	20.7%	21.9%	24.4%
Other Income ⓘ	166	208	229	358	477	369	270	322	512	747
Interest ⓘ	168	207	159	114	168	197	161	106	110	90
Depreciation ⓘ	505	754	1,323	1,323	1,326	1,175	1,068	1,052	1,172	1,051
Exceptional Items ⓘ	0	0	0	-78	0	0	0	-182	-182	-195
Profit Before Tax ⓘ	1,654	1,727	1,222	1,669	2,079	2,178	3,290	3,493	4,038	5,702
Tax ⓘ	400	332	180	250	570	631	889	934	1,203	1,547
Profit After Tax	1,254	1,395	1,042	1,419	1,510	1,547	2,401	2,559	2,835	4,155
PAT Margin (%)	11.1%	10.3%	7.2%	9.4%	9.2%	9.0%	12.5%	11.8%	12.5%	16.1%
Adjusted EPS (₹)	14.7	16.9	12.5	17.5	19.0	19.2	29.8	31.2	34.7	51.1
Dividend Payout Ratio (%)	14%	12%	16%	17%	16%	21%	17%	16%	24%	25%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	10,718	11,427	12,482	14,163	14,955	15,710	18,284	20,798	23,346	26,620
Share Capital ⓘ	161	161	161	161	161	161	161	161	161	161
Reserves ⓘ	10,558	11,266	12,321	14,002	14,794	15,549	18,123	20,636	23,185	26,458
Minority Interest	180	350	438	352	332	294	259	276	306	96
Debt	1,702	5,192	4,113	4,098	4,316	2,816	1,537	810	188	247
Long Term Debt	309	222	3,645	3,662	3,830	2,369	1,203	416	0	0
Short Term Debt	1,392	4,970	467	436	486	447	335	393	188	247
Trade Payables	1,452	1,476	1,571	2,119	1,948	2,282	2,067	2,508	2,535	2,474
Others Liabilities ⓘ	3,228	2,605	2,265	1,940	2,210	2,320	2,689	2,261	2,633	2,693
Total Liabilities ⓘ	17,281	21,049	20,869	22,673	23,762	23,423	24,837	26,652	29,007	32,130
Fixed Assets
Gross Block	9,562	10,168	11,353	12,960	13,790	14,914	15,647	16,968	17,205	18,161
Accumulated Depreciation	2,732	799	1,610	3,011	4,234	5,309	6,217	7,311	7,995	8,574
Net Fixed Assetsⓘ	6,830	9,368	9,743	9,949	9,557	9,604	9,430	9,658	9,210	9,587
CWIP ⓘ	581	2,061	1,683	981	676	825	969	766	1,093	1,153
Investmentsⓘ	639	758	973	1,259	2,554	1,471	2,710	2,551	3,662	5,449
Inventories	3,781	3,808	3,485	4,045	3,965	4,378	4,669	5,350	5,156	5,238
Trade Receivables	1,998	2,356	2,563	3,102	4,151	3,891	3,446	3,424	4,057	4,771
Cash Equivalents	564	871	624	966	619	1,004	1,401	1,928	1,565	875
Others Assetsⓘ	2,889	1,827	1,797	2,371	2,241	2,250	2,212	2,975	4,263	5,057
Total Assets ⓘ	17,281	21,049	20,869	22,673	23,762	23,423	24,837	26,652	29,007	32,130

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	1,173	1,741	2,382	1,463	1,691	3,068	3,755	3,326	3,238	4,134
PBT ⓘ	1,654	1,727	1,222	1,669	2,079	2,178	3,290	3,675	4,221	5,897
Adjustment ⓘ	630	951	1,374	1,294	1,269	1,366	1,131	967	878	641
Changes in Working Capital ⓘ	-719	-429	235	-778	-1064	373	372	-177	-559	-806
Tax Paid ⓘ	-392	-508	-450	-722	-593	-848	-1,037	-1,140	-1,302	-1,597
Cash Flow From Investing Activity ⓘ	-941	-4,523	-1,310	-854	-1,669	104	-2,387	-1,872	-2,389	-2,988
Capex	-626	-1,053	-1,098	-739	-504	-986	-791	-681	-1,134	-1,315
Net Investments	-38	0	-64	-282	-1,064	1,029	-1,675	153	-913	-1,473
Others ⓘ	-278	-3,470	-148	167	-101	61	80	-1,343	-341	-200
Cash Flow From Financing Activityⓘ	165	3,104	-1,326	-385	-349	-2,949	-1,240	-1,600	-958	-1,200
Net Proceeds from Shares ⓘ	12	3	12	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	7	-66	3,420	-3	-58	-1,736	-951	-1,041	-44	0
Interest Paid ⓘ	-167	-161	-159	-118	-159	-164	-121	-76	-65	-65
Dividend Paid ⓘ	-161	-159	-161	-161	-242	-564	0	-403	-404	-686
Others ⓘ	474	3,488	-4,438	-104	109	-485	-168	-80	-446	-449
Net Cash Flow ⓘ	397	322	-254	223	-326	224	129	-146	-109	-55

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	12.1	12.61	8.72	10.65	10.37	10.09	14.13	13.1	12.85	16.63
ROCE (%)	15.33	13.24	8.28	10.2	11.94	12.53	17.85	17.24	18.19	22.77
Asset Turnover Ratio	0.72	0.72	0.7	0.7	1.03	1.15	1.17	1.15	1.11	1.16
PAT to CFO Conversion(x)	0.94	1.25	2.29	1.03	1.12	1.98	1.56	1.3	1.14	0.99
Working Capital Days
Receivable Days	58	58	61	68	55	54	47	42	44	45
Inventory Days	106	100	91	90	61	56	58	62	62	54
Payable Days	104	105	105	124	128	129	108	98	112	104

Cipla Ltd Stock News

Cipla Ltd FAQs

What is the share price of Cipla?

Company share prices are keep on changing according to the market conditions. The closing price of Cipla on 21-Nov-2024 16:59 is ₹1,465.7.

What is the market cap of Cipla?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Cipla stood at ₹1,18,828.1.

What is the P/E ratio of Cipla?

The latest P/E ratio of Cipla as of 21-Nov-2024 16:59 is 28.07.

What is the P/B ratio of Cipla?

The latest P/B ratio of Cipla as of 21-Nov-2024 16:59 is 4.08.

What is the 52-week high and low of Cipla?

The 52-week high of Cipla is ₹1,702 and the 52-week low is ₹1,165.1.

What is the TTM revenue of Cipla?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Cipla is ₹14,965 ( Cr.) .

About Cipla Ltd

Cipla Limited is a global pharmaceutical company focused on responsible and sustainable growth of complex generics and deepening portfolio in home markets of India, South Africa and North America, as well as key regulated and emerging markets. Equity Shares of the Company are listed on Bombay Stock Exchange Limited and National Stock Exchange of India Limited.

Business area of the company

The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Products

Generics and branded generics
Specialty
Consumer health

Awards:

2013:

Ernst & Young awarded Dr. Y K Hamied with the Lifetime Achievement Award of the year 2013
Dr. Hamied honoured with the Greatest Global Indian Living Legend Award by NDTV
Viragaonagar unit won the Excellence Award in Environment Health & Safety (EHS)
Bagged the prestigious LegalEra Award for the Best Pharmaceutical in-house Legal team.

2014

Cipla won the Global L&D Team of the Year Award
Brand, Azee bagged the Marketing Excellence Award in 2014
Won the 'Silver' award from Pharmexcil for Outstanding Performance in the export of Pharmaceuticals
Network 18 and Infosys awarded Cipla for innovation on HIV/AIDS drugs

2015:

Won the Award for Excellence in Rural Reach at India Pharma Awards
Accredited to be in Top 10 of Hot 50 Brands in Mumbai, under ‘Large Organization Category’ at the Mumbai Brand Summit
Won the Social Contributors Award at the Annual Pitch Top 50 Brands Awards organized by Dainik Bhaskar
Best Company Award to focus in Overall Nursing Home Development at the first ever CIMS Healthcare Excellence Awards
ABP News honored Dr. Y.K. Hamied with the ‘Lifetime Achievement Award’ at the Brand Excellence Awards 2015

2016:

The Indian Manufacturers’ Association (IDMA) honoured Dr. Hamied with IDMA Lifetime Achievement Award for his outstanding contribution to the Indian pharmaceutical industry.
Moroccan Society of ENT honoured Cipla Morocco team for contribution to the education of the physics.
Dr. Y.K. Hamied was honoured with the Lifetime Achievement Award at the Forbes India Leadership Awards 2016.
Won two awards for Supplier Relationship Management and People Management at the CPO Awards 2016
Received an award for Acnedep Gel packaging at the 'India Packaging Awards' 2016
Won the ABP News Healthcare Leadership Award for excellence in managing Primary Care Practitioners

2017:

Digital team bagged two of the most prestigious awards of the digital world - Digital Pioneer of the year 2017 and Best company for leveraging technology in mobile application.
ActivKids Immuno Boosters won the Emerging Nutrition Brand of the Year awarded by CIMS.
Cipla Health won a place in the Economic Times Best Asian Healthcare Brands 2017

2018:

India Packaging Awards for Excellence in Enhanced User Experience for Mesalo Foam packaging
Silver Plasticon Award 2018 for Excellence and Innovation in flexible packaging for Acnedap Plus
SCMPro Logistics and Supply Chain Awards for 'Excellence in Pharma Supply Chain Management, Procurement Transformation of the Year' and 'Best Sourcing Analytics'.
Global Logistics Excellence Award for 'Best Digital Transformation in Pharma' in the Supply Chain Practitioners category
Breathefree website bags DMA Asia Echo Award (Silver) for Best Digital Destination and Leader Certificate in Pharma & Healthcare category
India Pharma Awards for Breathefree - 'Best Patient Outreach Programme of the Year', Digital Innovation
Indian Digital Awards (IDA) for Excellence in Digital Publishing
ABP News Healthcare Leadership Award for Excellence in Improving Awareness, Detection of Health Issues and Adherence to Treatment Regimen in the Emerging Markets

2019:

Cipla receives the 18th ICSI (Institute of Company Secretaries of India) National Award for Excellence in Corporate Governance in January 2019.
Highly Commended - 'Best Working Capital Management Solution Award' at the Adam Smith Awards Asia 2019
'Innovation in Generics' Award for Sereflo at the UK Pharmacy Business Awards 2019
‘Indo-American Corporate Excellence Award' for Excellence in Manufacturing (Category II) by the Indo-American Chamber of Commerce
Most Outstanding Company in India - Healthcare category at the Asiamoney Asia’s Outstanding Companies Poll 2019

2020:

Cipla Sri Lanka is Great Place to Work Certified
Cipla is Great Place to Work Certified
‘Digital Supply Chain Enterprise Award’ at the 9th edition of the Manufacturing Supply Chain Awards 2020
Golden Peacock Award for CSR 2019 in recognition of Cipla Foundation's significant contribution towards social change
What’s Up Cipla bags the 'Best Small Idea, Big Impact Communication of the Year' at the Corp Comm & PR Excellence Awards 2020
The Institute of Chartered Accountants of India Award for Excellence in Financial Reporting 2018-19 under the category of companies publishing integrated annual report

Milestones

1935: Operations commence from a rented bungalow at 289, Bellasis Road, Bombay Central.
1939: Mahatma Gandhi visits Cipla, inspiring the Founder Dr K A Hamied to produce vital and life-saving medicines for India.
1947: Cipla celebrates India attaining Independence with a flag hoisting ceremony at Bombay Central Headquarters.
1970: Cipla becomes one of the pioneers to manufacture APIs (active pharmaceutical ingredients).
1977: Inauguration of the Cipla Research and Production Complex in Bangalore by Mrs. Luba K Hamied.
1997: Cipla Palliative Care and Training Centre is set up in Pune to provide free holistic care to terminally-ill cancer patients and their families.
2001: Cipla ushers in a new paradigm in antiretroviral therapy (ART) by offering the triple ARV FDC at USD 1-a-day, thus opening the floodgates for affordability and accessibility in HIV/AIDS treatment.
2013: Cipla acquires 100% of share capital of Cipla Medpro (South Africa).
2016: Cipla strengthens its presence in the US market with the acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. thus expanding its reach in the US market, with a balanced portfolio.
2017: Cipla launches Synchrobreathe, a state of-the-art innovative breath-actuated inhaler, helping millions with Obstructive Airway Diseases such as asthma.
2019: Cipla enters digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa to bring together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients.
2020: Cipla leads the fight against COVID-19 through a spectrum of vital drugs that show potency against the virus. With unmatched portfolio of drugs and devices and leadership across India and key emerging markets, Cipla launches global lung leadership aspiration - Breathe. Think Cipla. In the US, the approval for generic AIbuterol MDI and successful Phase-3 completion of clinical study for generic Advair Diskus furthers this ambition.